Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Januar 2023 08:00 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
19. Dezember 2022 08:00 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Announces Financing Commitment for up to $60 Million

Funding from three leading healthcare investors, with Vivo Capital joining existing investors Nantahala Capital and Abingworth $10 million capital infusion at closing and $15 million upon positive...
09. November 2022 16:05 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
03. Oktober 2022 08:00 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics...
06. September 2022 08:00 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
10. August 2022 16:05 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
20. Juli 2022 08:00 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for...
11. Juli 2022 16:05 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference

REDWOOD CITY, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
13. Juni 2022 16:05 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS

REDWOOD CITY, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for...
07. Juni 2022 08:00 ET | Quelle: Soleno Therapeutics

Soleno Therapeutics Announces Presentations at ENDO 2022

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...

Vorherige Seite

Nächste Seite